Relmada Q2 net loss narrows; Phase 3 MDD trials on track for 2024

RELMADA THERAPEUTICS, INC.

2023-Q2 EPS reported -$1.72

Net loss $25.3M ($0.84/share) vs $39.9M ($1.33) in Q2 2022; R&D expense down to $13.7M from $30.9M.
Cash and short-term investments $118.5M at June 30; company says sufficiently funded for Phase 3 readouts in 2024.
Phase 3 Reliance II (302) enrollment ongoing; Relight (304) screening started; both expected to complete in 2024.
One-year open-label safety study (Reliance-OLS) completed; data expected later in the current quarter.
Human abuse potential data for REL-1017 published in peer-reviewed Translational Psychiatry.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported six months ended June 30, 2023 results: net income $51.6 million, EPS $1.72 per share.

Period: six months ended June 30, 2023
Net income: $51.6 million
EPS: $1.72 per share
Result: preliminary results

Exact text from the filing

Net loss for the six months ended June 30, 2023 and 2022 was $51.6 million and $79.7 million, respectively. The Company had a net loss of $1.72 and $2.73 per share for the six months ended June 30, 2023 and 2022, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income $25.3 million, or $0.84 per basic and diluted share, EPS $0.84 per basic and diluted share.

Period: second quarter ended June 30, 2023
Net income: $25.3 million, or $0.84 per basic and diluted share
EPS: $0.84 per basic and diluted share
Result: preliminary results

Exact text from the filing

Net loss for the three months ended June 30, 2023, was $25.3 million, or $0.84 per basic and diluted share, compared with a net loss of $39.9 million, or $1.33 per basic and diluted share, for the three months ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-064577

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.